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INTRODUCTION
Endometrial cancer is the most common gynecologic mali­
g  nancy in the United States, with approximately 42,160 new 
cases diagnosed in 2009 [1]. The majority of endometrial can­
cer patients present with early stage disease, which is asso  ci  a­
ted with a favorable prognosis. Nevertheless, recurrence rates 
are high in advanced stage disease; reported survival rates for 
patients with stage III or IV endometrial cancer range from 30­
89% and 0­10%, respectively [2­4]. 
Chemotherapy and whole abdominal radiotherapy (WAR) have 
been actively employed in the treatment of advanced en  do­
metrial cancer [5­7]. However, in comparison to WAR, systemic 
chemotherapy has demonstrated greater efficacy and more 
favorable patient outcomes [2]. Chemotherapy alone, none­
theless, has been associated with unfavorable pelvic relapse 
rates and appears inadequate at staving off loco­regional re­
currences [2,8]. Alternatively, when combining chemotherapy 
and irradiation, high risk endometrial cancer patients exhibited 
superior 3­year progression free (PFS, 62%) and overall sur  vival 
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Objective: The purpose of this retrospective study was to assess the tolerability and efficacy of sequential chemotherapy and 
radiotherapy for the treatment of high risk endometrial cancer.
Methods: We conducted a retrospective study of previously untreated high risk endometrial cancer patients who received 
sequential chemotherapy and radiotherapy in accordance with the sandwich approach from June 2008 until June 2011. High 
risk endometrial cancer patients underwent complete surgical staging followed by adjuvant therapy encompassing sequential 
chemotherapy, radiation therapy and consolidation chemotherapy.
Results: The study analysis comprised 32 endometrial cancer patients. All subjects were treated with carboplatin and paclitaxel 
chemotherapy; currently, 186 cycles have been administered and 94% of patients have completed the planned number of 
cycles. Grade 3 neutropenia developed in 1 (3.1%) patient; there was no incidence of grade 4 neutropenia. Moreover, we 
observed grade 3 anemia in four (12.5%) patients and grade 4 anemia in one (3.1%) patient. One (3.1%) patient developed grade 
3 thrombocytopenia; grade 4 thrombocytopenia was not observed. Five patients exhibited progressive disease, three of whom 
have since expired; mean progression free survival and follow­up were 17.4 months and 18.9 months, respectively.
Conclusion: The preliminary results from our study suggest that the sandwich approach to treating high risk endometrial cancer 
patients is feasible. Hematologic toxicity was well tolerated and non­hematologic toxicity was mild and easily managed. Further 
study of this novel regimen in a larger patient population with extended follow­up is necessary.
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(OS, 79%) compared to either radiotherapy (PFS, 59% and OS, 
70%) or chemotherapy alone (PFS, 19% and OS, 33%) [9]. 
One consideration in employing chemotherapy and radio­
therapy is the appropriate timing of treatment because of the 
the potential for alleviating patient toxicity. For example, in 
patients who commence with chemotherapy and develop 
toxicity, their capacity to complete radiotherapy may be 
compromised [10]. Conversely, when radiotherapy is initially 
administered, patients may be more susceptible to cancer 
progression from residual microscopic disease during the 
transitional period (i.e., prior to initiating chemotherapy) [9]. 
Studies have therefore, attempted to evaluate if the particular 
sequence in which adjuvant therapy is administered can miti­
gate toxicity and improve patient outcomes [4,9,11­13]. 
One such approach, the sandwich method, involves adju­
vant chemotherapy followed by radiotherapy and subsequent 
chemotherapy. In modifying the sequence of chemotherapy 
and irradiation, the hematologic toxicity is theoretically more 
manageable (i.e., a decreased incidence of dose delays and 
reductions), facilitating the administration of both treatments 
[11,12]. In another study involving endometrial cancer patients 
who were treated with the sandwich approach, the subjects 
were able to tolerate higher chemotherapy doses and experi­
enced a lower incidence of dose delays. Moreover, they exhi­
bited a 3­year PFS of 69% and an OS of 91% [13].
The sandwich approach potentially confers a more optimal 
prognostic benefit compared to conventional administration 
of chemotherapy and radiotherapy. The purpose of the cur­
rent retrospective study was to evaluate the efficacy and toxi­
city profile of sequential multi­modality sandwich therapy for 
the treatment of high risk endometrial carcinoma.
MATERIALS AND METHODS 
Following IRB approval, we conducted a chart review of 137 
newly diagnosed endometrial cancer patients who received 
adjuvant chemo­radiation therapy from June 2008 until June 
2011. From this group, we selected subjects who adhered to 
the following inclusion criteria: advanced stage or high risk 
endometrial cancer patients who underwent surgery and ad­
juvant sequential chemotherapy and radiotherapy followed 
by 3 additional cycles of chemotherapy. 
High risk endometrial cancer criteria included, but were not limi­
ted to, high grade (≥2), advanced stage, presence of lymph­vas­
cular space invasion, parametrial involvement, positive pelvic 
or para­aortic nodes, cervical or vaginal disease and myome­
trial invasion (outer one­third). Subjects underwent surgical 
staging comprised of total hysterectomy, bilateral salpingo­
oophorectomy, bilateral pelvic and para­aortic lymph node 
dissection and peritoneal cytology. Pelvic lymph node dissec­
tion typically encompassed the removal of lymphatic tissue 
from the anterior and medial surfaces of the iliac vessels and 
from the obturator distribution of the aforementioned nerve. 
Original pathologic reports were reviewed to determine his­
tologic type, FIGO stage, tumor grade, nodal status and identi­
fied sites of metastasis. Histologic diagnosis was confirmed in 
all cases via pathologic evaluation. Status of surgical cytore­
duction was determined per the physician’s operative notes. 
We defined optimal debulking as a maximum 1 cm diameter 
of residual disease following surgery [14]. 
Patients primarily commenced their chemotherapy regi­
men within 2­3 weeks of initial surgical debulking. All study 
patients were treated with carboplatin (area under the curve 
[AUC] 5 or 6) and paclitaxel (175 mg/m
2) every 21 days for an 
intended 3 cycles prior to the initiation of radiotherapy. Toxic­
ity was graded using the National Cancer Institute criteria [15].
Radiation therapy dosage and irradiated fields were deter­
mined by disease site, lymph node status and the discretion 
of the treating radiation oncologist. Prior to being irradiated, 
treatment planning was assessed to define the intended 
fields corresponding to the vaginal cuff, pelvic and para­aortic 
nodes, kidneys and small bowel. 
Select patients were treated with a total dose of external­
beam pelvic radiation of 50.4 Gy to the pelvis over 5 weeks 
with a daily fraction size of 1.8 Gy. Radiotherapy was admin­
istered via 4 field technique employing an 18 MV linear ac­
celerator with custom multi­leaf collimation blocking. Certain 
patients underwent intensity modulated radiation therapy 
(IMRT) to further mitigate the damage to healthy tissue. In 
patients with positive para­aortic nodes, the irradiated fields 
encompassed both pelvic and para­aortic chains. Conversely, 
if the para­aortic nodes were negative for metastatic disease, 
only the pelvic nodes were irradiated. Chemotherapy or radio­
therapy related dose delays or modifications were noted. 
Date of disease progression and site of recurrence were re­
corded. Recurrences were identified by histologic, radiologic 
or cytologic methods. PFS was defined as the period between 
initial surgical intervention and diagnosis of disease recur­
rence. OS was defined as the time from initial surgical treat­
ment until death with all causes of death treated equally. If a 
subject had not progressed or died, PFS was censored at the 
time of last follow­up. Long­term surveillance for patients oc­
curred via patient evaluation every 3 months for 3 years, semi­
annually for 2 years and then annually, thereafter.
1. Statistical methods
All statistical analyses were conducted using MedCalc statis­Lisa N. Abaid, et al.
http://dx.doi.org/10.3802/jgo.2012.23.1.22 24 www.ejgo.org
tical software for biomedical research (ver. 9.5.1 for Windows; 
MedCalc Software, Mariakerke, Belgium). Data analysis was 
initially conducted by employing a descriptive statistical ap­
proach and further explored via Kaplan Meier and Cox propor­
tional­hazards regression; significance (<0.05) was determined 
via 2­sided p­values. 
RESULTS
From the original group, we identified 33 subjects who un­
derwent surgical treatment and were either in the process of 
or completed adjuvant sequential chemotherapy and radio­
therapy in accordance with the sandwich approach. One pa­
tient was removed from the study during cycle one, electing 
to transfer her care to another medical facility; the subject’s 
data were excluded from the overall group analysis.
The predominant histologic subtype was endometrioid 
(n=19; 59.4%). In the present study population, 46.9% had 
poorly differentiated tumors, while 40.6% and 12.5% had 
moderately and well differentiated cancers, respectively. The 
patients’ clinical and pathologic characteristics are reported in 
Table 1. 
1. Adjuvant chemotherapy 
The total number of chemotherapy cycles administered to 
the 32 subjects at the conclusion of data collection was 186; 
94% of the patients completed the planned number of cycles. 
One patient withdrew from the study following cycle 3 after 
she developed a seizure and another was removed following 
cycle 4 due to grade 2 thrombocytopenia. Nevertheless, all 32 
patients were treated with 3 chemotherapy cycles prior to ra­
diation therapy; the median number of chemotherapy cycles 
subsequent to radiation therapy was 3 (range, 0 to 3). 
In terms or toxicity, grade 3 neutropenia was observed in 1 
(3.1%) patient; none of the subjects developed grade 4 neu­
tropenia. Moreover, four (12.5%) patients developed grade 
3 anemia and one (3.1%) patient exhibited grade 4 anemia. 
One (3.1%) patient exhibited grade 3 thrombocytopenia; we 
did not observe any grade 4 thrombocytopenia. There was no 
incidence of grade 3 or 4 neurotoxicity, although 1 (3.1%) pa­
tient developed grade 1 neuropathy (Table 2).
2. Radiotherapy
The mean total dose of radiation therapy was 4,722.81 +/­ 
583.82 cGY (95% confidence interval [CI], 4,512.32 to 4,933.30). 
The total dose prescribed to the pelvic region ranged from 
4,000 to 4,600 cGY. The median time from initiation of che­
motherapy to commencement of radiotherapy was 39 days 
(range, 22 to 61 days). The median number of radiation 
Table 2. Hematologic and non-hematologic events following che  mo-
therapy (n=32)
Grade Neutropenia Thrombocytopenia Anemia Neuropathy
1 1 (3.1) 0 (0) 2 (6.3) 1 (3.1)
2 2 (6.3) 2 (6.3) 0 (0) 0 (0)
3 1 (3.1) 1 (3.1) 4 (12.5) 0 (0)
4 0 (0) 0 (0) 1 (3.1) 0 (0)
Values are presented as number (%).
Table 1. Patients’ clinical and pathologic characteristics (n=32)
Characteristics Values
Mean age (yr) 67 (SD, 9.93)
Histology type
Endometrioid 19 (59.4)
UPSC 4 (12.5)
Clear cell 3 (9.4)
Mixed  3 (9.4)
Undifferentiated   3 (9.4)
FIGO stage
IA 3 (9.4)
IB 9 (28.1)
II 5 (15.6)
IIIA 5 (15.6)
IIIB 2 (6.3)
IIIC1 4 (12.5)
IIIC2 3 (9.4)
IVA 1 (3.1)
Grade
1 4 (12.5)
2 13 (40.6)
3 15 (46.9)
Cyto-reductive status
Optimal 29 (90.6)
Sub-optimal 3 (9.4)
Blood transfusion
No 29 (90.6)
Yes 3 (9.4)
G-CSF
No 28 (87.5)
Yes 4 (12.5)
Values are presented as number (%).
UPSC, uterine papillary serous carcinoma; FIGO, the International 
Federation of Gynecology and Obstetrics; G-CSF, granulocyte colony-
stimulating factor.Sequential chemo-radiation and high risk endometrial cancer
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therapy days was 46 days (range, 39 to 55 days). The inclusion 
of high dose rate (HDR) vaginal vault brachytherapy (700 cGY 
prescribed to the vaginal surface) was contingent upon the 
treating physician’s discretion. In the group of 32 patients, 7 
received vaginal brachytherapy. 
3. Dose delays
During the course of this review, there were only 3 dose 
delays, neither of which resulted in a dose reduction. Two 
chemotherapy dose delays were attributed to ≥grade 2 
thrombocytopenia or neutropenia. One patient experienced 
a radiotherapy related dose delay associated with grade 2 
colitis. Four patients received granulocyte colony­stimulating 
factor (G­CSF) to address ≥grade 2 neutropenia; three patients 
had a blood transfusion. 
4. Survival outcomes
Thus far, 5 patients have exhibited disease progression. There 
were two cases of recurrent disease in the vagina (stage II and 
IIIC2) and one case of progressive disease in the pelvis (stage 
IA). Moreover, one patient exhibited recurrent extra­pelvic 
disease (IIIC2) and another subject developed recurrent pul­
monary disease (stage IVA). The patients’ mean progression 
free survival was 17.4±6.56 months (95% CI, 15.00 to 19.74) 
(Fig. 1). While recognizing that a small sample size essentially 
precludes a sub­group analysis, we consider it noteworthy 
that 4 of the 5 progressive disease cases coincided with a high 
risk histology (uterine papillary serous carcinoma [UPSC]­3, 
clear cell­1); three patients have expired since the initiation of 
the study and overall survival is currently indeterminate. The 
patients’ mean duration of follow­up was 18.9±7.48 months 
(95% CI, 16.21 to 21.60). 
DISCUSSION
Chemotherapy and radiation therapy have frequently been 
employed in the treatment of advanced endometrial cancer 
[5­7,9]. There are, however, complications associated with 
ad  mi  nistering these two therapies [10­12]. Hence, to address 
these concerns, novel regimens such as the sandwich app­
roach, have been considered.
In the present sandwich therapy investigation for the treat­
ment of high risk endometrial cancer, we ascertained that one 
(0.5%) cycle was associated with grade 3 neutropenia, with no 
observed grade 4 neutropenia. Similarly, only one (0.5%) cycle 
was associated with grade 3 thrombocytopenia; there was no 
incidence of grade 4 thrombocytopenia. Grade 3 anemia co­
in  cided with 7 (3.77%) cycles and one (0.5%) cycle was asso  ci­
ated with grade 4 anemia. Grade 1 neuropathy was encoun­
tered with one cycle; non­hematologic toxicity was mild and 
easily managed. Nevertheless, the retrospective nature of this 
study limits a comprehensive assessment of toxicity.
Lupe et al. [12] employed 4 cycles of adjuvant chemotherapy, 
followed by radiotherapy and 2 additional cycles of chemo  the­
rapy for the treatment of advanced stage endometrial can  cer. 
They reported that the overall chemotherapy toxicity profile was 
acceptable; greater than 91% of chemotherapy cycles prior to 
radiotherapy were administered, but only 76% of the subse­
quent chemotherapy cycles were completed due to grade 3/4 
hematologic toxicity.
Fields et al. [11] studied the impact of sandwich therapy 
(paclitaxel and platinum chemotherapy, followed by pelvic 
radiotherapy and 3 additional cycles of chemotherapy) in op­
timally resected and staged UPSC patients. They encountered 
acceptable toxicity although grades 3 or 4 neutropenia were 
associated with 42% of the cycles. 
In our study, we reported an 84% PFS rate, which is higher 
than the 69% described by Secord et al. [9] and approximately 
55% in both the Fields et al. [11] and Lupe et al. [12] studies. 
One may conjecture that these PFS differences are attrib­
uted to diverse patient populations (e.g., variations in disease 
stage), different treatment regimens and duration of follow­
up. For example, Geller et al. [10] primarily (91% of patients) 
employed carboplatin and paclitaxel in their sequential multi­
modality therapy study for the treatment of high risk endome­
trial cancer; their reported 80.4% PFS was similar to our results. 
In a later study, Geller et al. [16] reported an 87% PFS following 
sandwich therapy with carboplatin and docetaxel, although 
their patient population was comprised of both advanced and 
recurrent endometrial cancer patients.
High risk endometrial cancer patients are vulnerable to local 
and distal recurrences, and thus, sandwich therapy may pro­
Fig. 1. Progression-free survival for high-risk endometrial cancer patients 
treated with sequential multimodal therapy.Lisa N. Abaid, et al.
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vide a therapeutic benefit; chemotherapy can assist with stav­
ing off upper abdominal disease following surgical staging 
and post radiotherapy potentially mitigates the risk for local 
recurrences [9,13]. In the current investigation, five patients 
developed recurrent cancer and the overall PFS was greater 
than 17 months; three patients exhibited progressive disease 
distally (e.g., pulmonary, pelvis or extra­pelvic) whereas two 
developed a vaginal recurrence. The majority (80%) of our 
progressive disease cases encompassed UPSC and clear cell 
tumors; this is consistent with previous studies that have cat­
egorized these tumor histologies as high risk [10,17] although 
one could speculate that our results are attributed to a stage 
phenomenon or a combination of these two factors.
In high risk endometrial cancer patients, the most frequent 
site of recurrence is the vagina [18]. Therefore, the inclusion of 
vaginal brachytherapy (VBT) for endometrial cancer patients 
with positive pelvic or para­aortic nodes, cervical or vaginal 
disease and parametrial involvement may be indicated [18­
21]. We employed VBT in less than 25% of patients, although 
the treatment potentially engenders a significant therapeutic 
benefit. For example, in the PORTEC­2 trial, high­intermediate 
risk endometrial carcinoma patients were randomized to 
either external beam radiotherapy (46 Gy) or to VBT (30 Gy); 
estimated 5­year vaginal recurrent rates were similar (1.8% for 
VBT and 1.6% for external beam radiotherapy [EBRT]) but loco­
regional relapse rates were more favorable in the VBT patients 
(2.1% vs. 5.1%) [18].
The data presented in this current analysis provide support 
for the hypothesis that sequential chemotherapy and radio­
therapy in accordance with moreover the sandwich approach 
may ultimately improve high risk endometrial cancer patient 
outcomes. The sandwich approach appeared to demonstrate 
reasonable activity and was well tolerated (i.e., there was a 
rea  sonably low incidence of dose delays or reductions). 
The current study has several limitations; in particular, an appre­
ci  ation of overall toxicity may be confounded in a retro  spective 
evaluation. Our definition of high risk endometrial cancer could 
be considered variable (i.e., low to high risk biologic behavior), 
which may explain the favorable outcomes in comparison to 
previous studies. Moreover, patient follow­up was not exten  si­
ve (18.9 months) and reporting bias is always a concern with in­
vestigational evaluations. We also recognize that the patients’ 
beneficial outcomes may reflect the preponderance of subjects 
with low to moderate grade or stage of disease; several of the study 
patients had endometrioid histology, in contrast to reported 
series [9,12].
The type of radiotherapy was also not delineated (i.e., we did 
not discern if there were prognostic differences amongst the 
patients who received pelvic radiotherapy (with or without 
ex  tended fields), vaginal brachytherapy alone or with pelvic 
ra  dio  therapy, and IMRT). In particular, the use of IMRT may 
have accounted for the reasonable toxicity encountered in 
the present study. Additional investigation of this novel regi­
men with a larger population of high risk endometrial cancer 
patients, even if only compared to a well­characterized con­
trol population, would strengthen the conclusions associated 
with the present analysis.
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